Search - tctmd.com

Displaying 101 - 120 of 259

Sort: Relevancy | Date

Presentation TCT 2016

Device Specifications and Clinical Program Update: Orbus-Neich Combo

Presenter: Alexandre Abizaid, Ashok Seth, Roxana Mehran

October 31, 2016

Presentation TCT 2016

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Presenter: John A. Bittl, Daniel I. Simon, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation CCVVC 2016

Optimal Duration of DAPT: Update on DAPT Guidelines

Presenter: Roxana Mehran

June 16, 2016

Presentation SOLACI 2016

The Unmet Needs of DES

Presenter: Roxana Mehran

June 09, 2016

Presentation Fellows 2016

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Roxana Mehran

April 15, 2016

Presentation Fellows 2016

Antiplatelet Therapy for the Interventionalist

Presenter: Roxana Mehran

April 15, 2016

Presentation JIM 2016

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Presenter: Roxana Mehran

February 11, 2016

Presentation JIM 2016

Self- Apposing Stents in STEMI:The Stentys Experience

Presenter: Roxana Mehran

February 10, 2016

$Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?$

Presentation TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

Contrast Nephropathy Clinical Trial Updates (AVERT, RenalGuard, Preserve, and Others)

Presenter: Somjot S. Brar, Richard Solomon, Roxana Mehran

October 15, 2015

Advertisement

Device Specifications and Clinical Program Update: Orbus-Neich Combo

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Levels of Evidence: Single-center vs Multicenter Trials

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Optimal Duration of DAPT: Update on DAPT Guidelines

The Unmet Needs of DES

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Antiplatelet Therapy for the Interventionalist

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Self- Apposing Stents in STEMI:The Stentys Experience

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Contrast Nephropathy Clinical Trial Updates (AVERT, RenalGuard, Preserve, and Others)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content